Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2008

Illumina and Genpathway Collaborate on Whole-Genome ChIP-Sequencing Services

  • Illumina and Genpathway are joining forces to provide whole-genome ChIP sequencing. The combined services will help identify and quantify transcription-factor binding sites across the entire genome.

    Samples will be prepared using Genpathway’s FactorPath ChIP assays and sequenced by Illumina’s Genome Analyzer through its sequencing services. Genpathway  will do the final data analysis. The combined services will also include cell or tissue processing, antibody selection and qualification, and quality-control steps throughout the assay.

    “One of the top applications for sequencing is ChIP, a notoriously time-consuming and difficult procedure,” points out Mary Harper, Ph.D., CSO of Genpathway. “Combining Genpathway’s expertise in ChIP and data-analysis services with Illumina’s high-throughput next-generation sequencing technology and services provides researchers a faster path to discovery.”



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »